Acalabrutinib + Obinutuzumab

Phase 2Recruiting

0 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Grade 1 Follicular Lymphoma

Conditions

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-Hodgkin Lymphoma, Lymphoplasmacytic Lymphoma, Lymphoproliferative Disorder, Mantle Cell Lymphoma, Marginal Zone Lymphoma

Trial Timeline

Sep 3, 2021 → Jan 15, 2027

NCT ID

NCT04883437

About Acalabrutinib + Obinutuzumab

Acalabrutinib + Obinutuzumab is a phase 2 stage product being developed by AstraZeneca for Grade 1 Follicular Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04883437. Target conditions include Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma.

What happened to similar drugs?

0 of 7 similar drugs in Grade 1 Follicular Lymphoma were approved

Approved (0) Terminated (1) Active (6)

🔄diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + PlaceboNovartisPhase 3

❌MEK162, MEK inhibitor; oral + Physician's choice chemotherapyPfizerPhase 3

🔄rituximabBiogenPhase 3

🔄Tovorafenib + Chemotherapeutic AgentDay One BiopharmaceuticalsPhase 3

🔄Remestemcel-LMesoblastPhase 3

🔄remestemcel-LMesoblastPhase 3

🔄avutometinib + Defactinib + Pegylated liposomal doxorubicin + Paclitaxel + Letrozole + AnastrozoleVerastem OncologyPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05950997	Pre-clinical	Recruiting	Apr 16, 2024	Sep 30, 2026	Chronic Lymphocytic Leukemia
NCT04883437	Phase 2	Recruiting	Sep 3, 2021	Jan 15, 2027	Grade 1 Follicular Lymphoma
NCT04722172	Phase 2	Active	May 21, 2021	Feb 1, 2026	Chronic Lymphocytic Leukemia
NCT03198650	Phase 1	Active	Jun 27, 2017	Dec 31, 2025	Part1: Advanced B-cell Malignancies

Competing Products

20 competing products in Grade 1 Follicular Lymphoma

See all competitors

Product	Company	Stage	Hype Score
[203Pb]VMT-α-NET	Perspective Therapeutics	Phase 1	27
azenosertib	Zentalis Pharmaceuticals	Phase 2	32
Sepantronium Bromide	Cothera Bioscience	Phase 2	29
DS-1001b	Daiichi Sankyo	Phase 2	39
Rabeprazole Sodium	Eisai	Pre-clinical	26
Binimetinib 15 MG	Ono Pharmaceutical	Phase 2	42
Abemaciclib + Letrozole	Eli Lilly	Phase 2	42
Pirtobrutinib + Mosunetuzumab	Eli Lilly	Phase 2	42
Pembrolizumab + Pemetrexed + Abemaciclib	Eli Lilly	Phase 1	21
DSP-0390	Sumitomo Pharma	Phase 1	33
Mirvetuximab soravtansine + Carboplatin	AbbVie	Phase 2	39
Mirvetuximab Soravtansine	AbbVie	Phase 2	42
Olaparib Pill + AZD6738	AstraZeneca	Phase 2	35
Pembrolizumab	Merck	Phase 2	42
Efineptakin alfa + Pembrolizumab	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	39
Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + Docetaxel	Merck	Phase 2	35
Cilengitide	Merck	Phase 2	31
Avelumab	Merck	Phase 2	35
Human Papillomavirus vaccine	Merck	Phase 2	35